You’re offline. This is a read only version of the page.
Caroline Barelle was made redundant from her position as a team leader for a large pharmaceutical company, however from this came an opportunity with the University of Aberdeen to spin-out a new biotech company. Elasmogen Ltd is rapidly progressing a pipeline of next-generation therapeutic biologics called “soloMERs” for the sight saving treatment of inflammatory diseases of the eye and inflammatory conditions of the gut. The small size and robust nature of soloMERs enables site-specific delivery of these molecules thereby avoiding the need for needles and potentially damaging systemic drug exposure.
The Company’s primary clinical indication is sight-saving treatment of neovascular retinopathies including age-related macular degeneration (AMD), diabetic macular edema (DME) and the inflammatory eye disease, uveitis. The Company is also collaborating with a number of high quality biopharma partners such as Amgen Inc and Feldan Ltd for the intracellular localisation of novel soloMERs into cells and cell compartments and Merck for to enhance their bioprocessing process for therapeutic antibodies. The utility of soloMERs in cancer indications is also being progressed through the development of soloMER-drug conjugates in collaboration with Almac Discovery and novel soloMER-coated nanoparticles in partnership with Queen’s University Belfast.
In 2015, Caroline led Elasmogen Ltd to victory, securing the Converge Challenge runner-up prize.
“We were absolutely delighted to be runners-up in the Converge Challenge. I personally gained a huge amount from the support and commercial expertise during the process and the prize itself elevated the profile of the company and opened up many new opportunities.”
Elasmogen Ltd have received investment from Biological Sciences Research Council and Scottish Enterprise. Caroline received a BBSRC/Royal Society of Edinburgh Enterprise Fellowship which enabled them to establish the company in 2016. Since spinning out, Elasmogen has expanded the team to seven employees and formed a strong board. Caroline and her team have also gone on to win several awards including the Perfect Pitch at BioTrinity 2016 conference, and were also shortlisted for the OBN Awards.
In 2017, they secured £1.2 M in grant and equity investment from Deepbridge Capital, Innovate UK and the Scottish Investment Bank.
2018 looks like another successful period for the company as it entered the new year with additional investment from DBC which will enable the company the complete critical pre-clinical studies, adding value to the portfolio.
https://www.elasmogen.com/